Claseprubart's Differentiated C1s Inhibition Positions Dianthus to Disrupt the Complement Inhibitor Market

Core Conclusion

Dianthus’ claseprubart has shifted from a competitive-class asset to a potential best-in-disease complement inhibitor, driven by upstream C1s selective inhibition, a ~7x potency advantage over riliprubart and 30–40x over empasiprubart, and early CAPTIVATE CIDP interim data that exceeded internal expectations. Management now frames the program as effectively de-risked and capable of challenging FcRn and C5 therapies, with first-line or early-switch adoption in MG, CIDP, and MMN. The key debate centers on whether Phase 3 will confirm superiority, but the convergence of trial design, potency, and mechanistic differentiation creates a high-conviction thesis.

What the Market May Be Underestimating

Investors may be undervaluing two dimensions. First, upstream C1s inhibition prevents formation of C3a and C3b, offering more complete disease control than downstream C5 or indirect FcRn blockade—not just a safety advantage but a potential efficacy step-change. Second, the CAPTIVATE trial design (no IVIg washout, stricter responder criteria requiring sustained improvement across consecutive visits) makes the early efficacy signal more clinically relevant and harder to dismiss than prior FcRn studies. The implied response rate in the mid-to-high-70% range, derived from the early GO decision after ≥20 responders, likely understates the true signal because it excludes potential late responders and washout effects from the broad inclusion of naïve, stable, and refractory patients.

Evidence Chain

CAPTIVATE interim data exceeded internal expectations. The early GO decision was triggered after ≥20 responders before the planned cohort completed enrollment. Management characterized the data as “exceeding internal expectations,” with investor reconstruction pointing to an implied response rate in the mid-to-high-70% range. The trial enrolled a broad population (naïve, stable, refractory), with consistent responses across subgroups—particularly strong in naïve patients.

Claseprubart’s selective C1s inhibition provides a differentiated mechanism. Upstream blockade avoids complete complement cascade shutdown, preserving immune function and reducing risks such as drug-induced lupus associated with C1q inhibition or infection risk from terminal complement blockade. This allows the molecule to target C5-like efficacy while improving safety, a combination that management believes enables a superior risk-benefit profile.

Potency advantage is quantifiable and clinically translatable. Management repeatedly cited in vitro data showing claseprubart is approximately 7x more potent than riliprubart and 30–40x more potent than empasiprubart. This differential is central to the program’s “de-risked” characterization, as management sees direct translation from potency to clinical outcomes.

Development timelines are converging with competitors. Management acknowledged a 12–18 month lag vs Sanofi’s riliprubart but believes the gap can narrow. Dense near-term catalysts include CAPTIVATE Part B progress, MMN Phase 2 data (Q4 2026), MG Phase 3 initiation (mid-2026), DNTH212 Phase 1 data (2H26), and ARGX empasiprubart Phase 3 MMN data (2H26). With $1.2bn cash and runway into 2030, Dianthus can fully execute Phase 3 and commercial build.

Key Divergences and Risks

Phase 3 superiority is not guaranteed. The thesis hinges on claseprubart demonstrating incremental efficacy over riliprubart and FcRn inhibitors in CIDP and MG. If superiority fails—especially in the more stringent CAPTIVATE design—the story collapses to a me-too asset with a delayed market entry. Early data are promising but not definitive.

Riliprubart’s first-mover advantage could entrench market share. Even if claseprubart shows comparable or slightly better efficacy, a 12–18 month head start for riliprubart in building physician familiarity, trial experience, and formulary access may create a durable competitive barrier. Sanofi’s commercial infrastructure amplifies this risk.

Pricing and reimbursement depend on superiority over IVIg. Management’s strategy targets a value-based price relative to emerging benchmarks, but payer acceptance will hinge on showing superior outcomes vs IVIg, the current standard. If superiority is marginal or not statistically convincing, pricing power may be limited.

Safety profile may change with larger exposure. While upstream C1s inhibition theoretically avoids lupus-like AEs and infection risk, immune complex-mediated events could emerge in larger populations. The current favorable risk-benefit assessment is based on limited data.

Valuation and Trade Implications

Dianthus is not covered by MS, so no rating or target. If Phase 3 confirms superiority, claseprubart could reshape the complement inhibitor market. In MG, fewer than 20% of patients use biologics; in CIDP, IVIg dominates despite tolerability challenges. Peak sales could reach several billion dollars, with first-line positioning.

Cash of $1.2bn (March 2026) supports execution through 2030, eliminating near-term financing risk. The key validation points are: CAPTIVATE Part B complete data (potentially late 2026) and MMN Phase 2 readout (Q4 2026). Until then, the thesis relies on management’s increased confidence and trial design quality. Investors should track these catalysts as the binary event that will either confirm claseprubart as a best-in-disease asset or relegate it to a competitive also-ran.

Appendix Data Summary

Table 1: Claseprubart vs Key Competitors – Potency, Mechanism, and Safety

Table 2: Dianthus Near-Term Catalyst Timeline (Next 12–18 Months)